Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drug Pricing

Reports

Displaying 1 - 10 of 21. 10 per page. Page 1.

Advanced Search
ASPE Issue Brief

Trends in Prescription Drug Spending, 2016-2021

September 30, 2022
High prescription drug costs are a leading concern among Americans. Americans pay higher prices for prescription drugs than any other country in the world, with prescription drug prices in the U.S. more than 2.5 times as high as those in other similar high-income nations.

Price Increases for Prescription Drugs, 2016-2022

September 30, 2022
Prescription drug price increases create affordability challenges for patients and for the government. This report tracks drug price changes from 2016-2022. There were 1,216 products whose price increases during the twelve-month period from July 2021 to July 2022 exceeded the inflation rate of 8.5 percent for that time period. The average price increase for these drugs was 31.6 percent.
Report

International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies

July 1, 2022
Key Findings Policy discussion surrounding U.S. prescription drug prices focuses on whether prices in the United States are too high or appropriate relative to the benefits that they offer to patients.
Report

Assessing Relationships between Drug Shortages in the United States and Other Countries

October 13, 2021
Drug shortages are a persistent public health problem in the United States and in other countries. Shortages can have important implications for the health care systems and pharmacies that purchase, store, and dispense drugs and for the patients who rely on the availability of drugs to treat and prevent disease.
ASPE Issue Brief

Medicare Part D: Competition and Generic Drug Prices, 2007-2018

January 26, 2021
The United States relies on the interactions of private entities – drug manufacturers, health plans and pharmaceutical benefit managers (PBMs) - to achieve value by negotiating prices, operating formularies and implementing other benefit management strategies. The U.S. does not establish or negotiate prices for prescription drugs, as do some other countries. A critical part of the U.S.

Comparing Insulin Prices in the U.S. to Other Countries

September 23, 2020
Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach.
Report to Congress

Report to Congress: Prescription Drugs: Innovation, Spending, and Patient Access

September 25, 2019
This Report responded to a request from the House and Senate Committees on Appropriations.
Report to Congress

Report to Congress: Prescription Drug Pricing Report

September 25, 2019
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.

Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures

October 24, 2018
The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as exmanufacturers prices) in the United States are 1.8 times higher than in other countries for the top drugs by total expenditures separately paid under Medicare Part B. U.S. prices were higher for most of the drugs included in the analysis, and U.S.
ASPE Data Point

Data Point: Savings Available Under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D

July 22, 2018
ASPE analyzed Part D prescription drug event data from 2016 to estimate spending on brand drugs with generic therapeutic equivalents.